| Lanny R Schneider, PA | |
|
2702 8th Ave N, Billings, MT 59101-1107 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Lanny R Schneider |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 20 Years |
| Location | 2702 8th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922071414 | NPI | - | NPPES |
| 000097893 | Other | MT | BCBS PIN |
| 4309981 | Other | MT | MDCD PIN |
| 121783600 | Medicaid | WY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy.
For patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
A new study from Texas Biomedical Research Institute (Texas Biomed) and collaborators has identified a promising drug candidate to minimize uncontrolled, erratic muscle movements, called dyskinesia, associated with Parkinson's disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lanny R Schneider, PA Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Lanny R Schneider, PA 2702 8th Ave N, Billings, MT 59101-1107 Ph: (406) 238-2500 |
News Archive
Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy.
For patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
A new study from Texas Biomedical Research Institute (Texas Biomed) and collaborators has identified a promising drug candidate to minimize uncontrolled, erratic muscle movements, called dyskinesia, associated with Parkinson's disease.
› Verified 8 days ago